Doctor and patient

What we do

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.

Chk1 was licensed to Sierra Oncology, inc. (NASDAQ:SRRA) in September 2016. We are currently pursuing our other drug discovery and development programmes in collaboration with Hebei Medical University Biomedical Engineering Center (Aurora+FLT3) and SRI International (TYK2 Autoimmune) whilst TYK2 Cancer is funded internally.


Further Information

Find out more about our drug development programs

Sareum brochure